Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis

July 2006
CMAJ: Canadian Medical Association Journal;7/4/2006, Vol. 175 Issue 1, p48
Academic Journal
Focuses on the clinical practice guidelines published by Osteoporosis Canada for the diagnosis and management of osteoporosis in Canada. Evidence for the use of anti-resorptive agents in the management of osteoporosis in 2002; Formation of new bone due to anabolic agents; Review of trials evaluating parathyroid hormone for the treatment of osteoporosis.


Related Articles

  • Recombinant Full-Length Parathyroid Hormone (1-84). Moen, Marit D.; Scott, Lesley J // BioDrugs;2007, Vol. 21 Issue 3, p205 

    The article discusses the importance of recombinant full-length parathyroid hormone in treating osteoporosis. Osteoporosis occurs when the rate of bone resorption exceeds the rate of bone formation. The resulting loss of bone mass and strength can lead to fragility fractures. Available...

  • Recombinant Full-Length Parathyroid Hormone (1-84): A Viewpoint by James Whitfield. Whitfield, James // Drugs;2006, Vol. 66 Issue 18, p2382 

    â–´ The fentanyl buccal tablet (FBT) is a new formulation of fentanyl that uses an effervescent drug delivery system to enhance penetration across the buccal mucosa for the treatment of breakthrough pain in opioid-tolerant patients with cancer.â–´ Fentanyl is rapidly absorbed from FBT...

  • Targeting Vascular Niche by Parathyroid Hormone. Pagliarulo, Caterina; Salvatore, Paola; Napoli, Claudio // Current Medicinal Chemistry;2008, Vol. 15 Issue 28, p2984 

    Currently, the parathyroid hormone (PTH) is a drug approved for use in humans only in bone metabolism diseases, as the osteoporosis. The PTH acts primarily by binding to its principal receptor, PTH/PTHrP-R, a member of the class B G protein-coupled receptor (GPCR) family that includes together...

  • bmj updates.  // BMJ: British Medical Journal (International Edition);8/12/2006, Vol. 333 Issue 7563, preceding p311 

    The article provides a summary of the article "Parathyroid hormone for the treatment of osteoporosis: a systematic review," by A. Cranney, et al. The study evaluated the use of parathyroid hormone as a treatment for osteoporosis in women. The research found that the use of parathyroid hormone...

  • Therapy of Male Osteoporosis with Parathyroid Hormone. Bilezikian, J.P.; Kurland, E.S. // Calcified Tissue International;Oct2001, Vol. 69 Issue 4, p248 

    Definable causes of male osteoporosis account for only about 60% of the osteoporotic population. Those for whom no etiology is readily apparent are said to have primary or idiopathic male osteoporosis. In these individuals, histomorphometric studies indicate that this is a disorder that is more...

  • Improvement of trochanteric bone quality in an osteoporosis model after short-term treatment with parathyroid hormone: a new mechanical test for trochanteric region of rat femur. Tezval, M.; Stuermer, E. K.; Sehmisch, S.; Rack, T.; Stary, A.; Stebener, M.; Konietschke, F.; Stuermer, K. M. // Osteoporosis International;Feb2010, Vol. 21 Issue 2, p251 

    We have examined the changes induced in the trochanteric region of femur of ovariectomized rat after administration of estradiol and p.arathyroid hormone. We have developed a reproducible biomechanical test and produced trochanteric fractures to evaluate stiffness and strength of this region in...

  • PTH-vitamin D analogue combination shows therapeutic promise.  // Geriatrics;Mar1991, Vol. 46 Issue 3, p83 

    The article reports that a combined regimen of a new parathyroid hormone derivative and the vitamin D analogue calcitriol can cause dramatic increases in the vertebral bone mass of women with established osteoporosis. In 15 women with advanced osteoporosis treated with the two agents for two...

  • 1 year of alendronate after 1 year of parathyroid hormone (1-84) treatment increased bone mineral density in osteoporosis: COMMENTARY. Jamal, Sophie A. // ACP Journal Club;Jan/Feb2006, Vol. 144 Issue 1, p10 

    This article comments on a study conducted to examine the efficacies of alendronate and parathyroid hormone (PTH) in increasing bone mineral density (BMD) in osteoporosis. In the study, researchers reported that the increases in BMD observed after 1 year of PTH were lost if therapy was stopped...

  • Parathyroid hormone for the treatment of osteoporosis: a systematic review. Cranney, Ann; Papaioannou, Alexandra; Zytaruk, Nicole; Hanley, David; Adachi, Jonathan; Goltzman, David; Murray, Timothy; Hodsman, Anthony // CMAJ: Canadian Medical Association Journal;7/4/2006, Vol. 175 Issue 1, p52 

    Background: Human parathyroid hormone (hPTH)(1-34) was approved in 2004 for the treatment of severe osteoporosis. Members of the Osteoporosis Canada clinical guidelines committee conducted a systematic review of randomized controlled trials (RCTs) to assess the efficacy and safety of hPTH for...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics